CJC-1295 with DAC Research & Studies
Part of the full CJC-1295 with DAC guide - a synthetic growth-hormone-releasing hormone reference compound, identity-verified with a COA on every vial.
In brief
Research framing for CJC-1295 with DAC, as captured in this entry, clusters around its identity as an albumin-binding GHRH analog: how its GRF(1-29) backbone engages the growth-hormone-releasing-hormone receptor, how the maleimide-to-albumin chemistry was established, and what the secretagogue signal output looks like in the cited models. The provided citations are specific and bounded, so this spoke attributes each research thread only to the sources actually listed in the entry: Teichman et al. 2006 (PMID 16352683), Ionescu and Frohman 2006 (PMID 17018654), Leger et al. 2004 (PMID 15357960), Halmos et al. 2025 (PMID 39934495), and Frohman, Downs and Chomczynski 1992 (PMID 1360911). The listed research areas span receptor-binding and Gs/adenylate-cyclase/cAMP assays, somatotroph pathway and GH-gene transcription models, the bioconjugation chemistry itself, proteolytic-stability characterization, the albumin-binding half-life-extension platform, and the pulsatility of secretagogue-driven hormone release in physiological models.
The detail
A closer look
01
Receptor and signaling literature
The receptor-level grounding comes from Halmos et al. 2025 in Reviews in Endocrine and Metabolic Disorders (PMID 39934495), a review of the growth-hormone-releasing hormone receptor (GHRH-R) and its signaling, cited in the entry for the identification of GHRHR as a class-B secretin-family Gs-coupled GPCR on somatotrophs. Upstream regulatory context is supplied by Frohman, Downs and Chomczynski 1992 in Frontiers in Neuroendocrinology (PMID 1360911) on the regulation of growth hormone secretion. Together these define the in-vitro and physiological backdrop for the listed research areas covering GHRHR receptor-binding and Gs/adenylate-cyclase/cAMP signaling assays and the somatotroph cAMP/PKA/CREB pathway with GH-gene transcription models. These are the authoritative anchors for treating the molecule as a GHRHR ligand rather than relying on vendor descriptions, and they bound what can responsibly be said about its receptor pharmacology.
02
Bioconjugation and stability research
The chemistry thread is anchored by Leger et al. 2004 in Bioorganic and Medicinal Chemistry Letters (PMID 15357960), cited for the DAC mechanism in which a maleimide forms a covalent thioether to albumin Cys34 at 1:1 stoichiometry with roughly 1000-fold accelerated reactivity versus other thiols, and for the DPP-IV resistance conferred by D-Ala2 and the other backbone substitutions. Notably, that paper is titled for a CJC-1131-albumin bioconjugate as a stable, bioactive GLP-1(7-36) analog, underscoring that the cited work establishes the ConjuChem DAC platform chemistry generally rather than CJC-1295 specifically. This maps onto two listed research areas: maleimide-to-albumin-Cys34 site-selective bioconjugation chemistry, and peptide proteolytic-stability and DPP-IV-resistance characterization. The research value here is the conjugation and stability platform that underlies the molecule's design.
03
Secretagogue signal output and pulsatility
The functional-output evidence comes from Teichman et al. 2006 in JCEM (PMID 16352683) and Ionescu and Frohman 2006 in JCEM (PMID 17018654). Teichman et al. is cited for a reported plasma half-life estimate of 5.8 to 8.1 days after a single subcutaneous dose, and, with Ionescu and Frohman, for the signal output the entry records: a single dose raising mean plasma GH roughly 2 to 10-fold for more than six days and IGF-1 roughly 1.5 to 3-fold for nine to eleven days, with preserved GH pulsatility and no rise in prolactin, cortisol, or ACTH. Ionescu and Frohman specifically address persistence of pulsatile GH secretion during continuous stimulation, mapping to the listed research area on pulsatility of secretagogue-driven hormone release in physiological models. These citations are the sole basis for any quantitative signal claims in this reference.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. CJC-1295 with DAC is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.